Overview

Paclitaxel in Treating Patients With Refractory or Recurrent Acute Leukemia or Chronic Myelogenous Leukemia

Status:
Completed
Trial end date:
2000-07-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I/II trial to study the effectiveness of paclitaxel in treating patients with refractory or recurrent acute leukemia or chronic myelogenous leukemia.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Swiss Group for Clinical Cancer Research
Treatments:
Albumin-Bound Paclitaxel
Paclitaxel